TIGIT

News
Card image cap

GSK, iTeos take stock after Roche's TIGIT setback

iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT drug EOS-448 following the failure of a key trial for Roche'

News
Card image cap

Roche's TIGIT ambitions take another blow

Roche's anti-TIGIT antibody tiragolumab has failed a second phase 3 trial, dousing expectations for the programme and its hopes of finding a companion to its cancer immunotherapy blockbuste